Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma

No abstract is available for this paper.

• Publication year

  2021

• Venue

  Nature Medicine

• Publication date

  2021-02-22

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/s41591-021-01245-5PMID 33619368
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A T CELL REDIRECTING BISPECIFIC G-PROTEIN COUPLED RECEPTOR CLASS 5 MEMBER DxCD3 ANTIBODY TO TREAT MULTIPLE MYELOMA.

  2020cited by this paper
• Abstract Book: 25th Congress of the European Hematology Association Virtual Edition, 2020

  2020cited by this paper
• Revealing the impact of structural variants in multiple myeloma.

  2020cited by this paper
• Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape-Driven Relapse in Multiple Myeloma.

  2020cited by this paper
• B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches

  2020cited by this paper
• Treatment of Recurrent Refractory Pediatric Pre-B Acute Lymphoblastic Leukemia Using Inotuzumab Ozogamicin Monotherapy Resulting in CD22 Antigen Expression Loss as a Mechanism of Therapy Resistance

  2019cited by this paper
• B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma.

  2019cited by this paper
• Anti‐BCMA CAR T‐Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

  2019cited by this paper
• Trispecific antibodies offer a third way forward for anticancer immunotherapy

  2019cited by this paper
• Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)

  2019cited by this paper
• UMAP: Uniform Manifold Approximation and Projection

  2018cited by this paper
• Estimating pseudocounts and fold changes for digital expression measurements

  2018cited by this paper
• Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia

  2018cited by this paper
• Strelka2: fast and accurate calling of germline and somatic variants

  2018cited by this paper
• Integrating single-cell transcriptomic data across different conditions, technologies, and species

  2018cited by this paper
• T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.

  2018cited by this paper
• SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes.

  2017cited by this paper
• Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma

  2017cited by this paper
• Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing

  2017cited by this paper
• Axicabtagene Ciloleucel CAR T‐Cell Therapy in Refractory Large B‐Cell Lymphoma

  2017cited by this paper
• Pan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors

  2017cited by this paper
• Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma.

  2016cited by this paper
• Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications

  2016cited by this paper
• APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment.

  2016cited by this paper
• Single-cell RNA-seq reveals changes in cell cycle and differentiation programs upon aging of hematopoietic stem cells

  2015cited by this paper
• CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma.

  2013cited by this paper
• A smart local moving algorithm for large-scale modularity-based community detection

  2013cited by this paper
• Isaac: ultra-fast whole-genome secondary analysis on Illumina sequencing platforms

  2013cited by this paper

• Mapping clinical CAR-T cells: insights from scRNA-seq.

  2026cites this paper
• The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D.

  2026cites this paper
• Pathways of Resistance: Modern Multiple Myeloma Therapies and Overcoming Reliance on Genomic Integrity

  2026cites this paper
• TIGIT disruption rescues the antitumor activity of low avidity TCR-engineered T cells by increasing TCR signal strength

  2026cites this paper
• Tailored strategies for improved control of CAR-T cells in multiple myeloma

  2026cites this paper
• Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myeloma.

  2026cites this paper
• Antibody-Drug Conjugates, T-Cell Engager Bispecific Antibodies and Chimeric Antigen Receptor T Cells for Multiple Myeloma: What’s the Current Status?

  2026cites this paper
• Overcoming functional and translational challenges of cellular immunotherapies for solid tumors.

  2026cites this paper
• Enhanced antitumoral activity of the academic CAR-T ARI0002h against normal and low BCMA-expressing myeloma cells after incorporating a transmembrane CD28 domain

  2026cites this paper
• The ancestral haplotype of P2RX5 yields a B-cell surface marker and a multi-lineage immunotherapy target

  2026cites this paper
• Determinants of Efficacy and Optimization of Chimeric Antigen Receptor T-Cell Therapy for Treating Multiple Myeloma: Current Status and Future Perspectives.

  2026cites this paper
• From Multi‐Omics to Visualization and Beyond: Bridging Micro and Macro Insights in CAR‐T Cell Therapy

  2025cites this paper
• Sequencing BCMA‐ and GPRC5D‐targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network

  2025cites this paper
• Targeting B-cell maturation antigen in relapsed or refractory multiple myeloma: On the verge of its prime time.

  2025cites this paper
• Strategies for salvage therapy post CAR-T therapy failure in refractory/relapsed multiple myeloma patients

  2025cites this paper
• Single-Cell Multiomics Reveals Regulatory Mechanisms of CAR T Cell Persistence and Dysfunction in Multiple Myeloma

  2025cites this paper
• Unique molecular assay (UMA): a next-generation sequencing targeted panel for efficient and comprehensive genomic profiling and risk stratification of multiple myeloma

  2025cites this paper
• Strategies to Overcome Antigen Heterogeneity in CAR-T Cell Therapy

  2025cites this paper
• Utilizing genomics to identify novel immunotherapeutic targets in multiple myeloma high-risk subgroups

  2025cites this paper
• Engineered T cells secreting αB7-H3-αCD3 bispecific engagers for enhanced anti-tumor activity against B7-H3 positive multiple myeloma: a novel therapeutic approach

  2025cites this paper
• Solving Riddles Through Sequencing (SIRIUS): unlocking hematologic diagnoses by whole genome and transcriptome sequencing

  2025cites this paper
• Targets Selection for Precision Therapy of Relapsed/Refractory Multiple Myeloma: the Latest Advancements

  2025cites this paper
• Myeloma cell intrinsic ANXA1 elevation and T cell dysfunction contribute to BCMA-negative relapse after CAR-T therapy.

  2025cites this paper
• Aberrant single-cell phenotype and clinical implications of genotypically defined polyclonal plasma cells in myeloma

  2025cites this paper
• CAR-T cell therapy for patients with extramedullary multiple myeloma：Opportunities and challenges.

  2025cites this paper
• Immuntherapien des multiplen Myeloms

  2025cites this paper
• Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial

  2025cites this paper
• SMAD4 Regulates the Expression of LCK Affecting Chimeric Antigen Receptor‐T Cells Proliferation Through PI3K/Akt Signaling Pathway

  2025cites this paper
• BCMA biology and therapeutic targeting in multiple myeloma: From ligand signaling to antigen escape.

  2025cites this paper
• Outnumbered: T-cell dominance breaks BCMA-TCE resistance.

  2025cites this paper
• Single-cell sequencing reveals the mechanisms of multiple myeloma progression: clarity or confusion?

  2025cites this paper
• Integrated clinical and single-cell profiling of BCMA CAR-T therapy in relapsed/refractory multiple myeloma

  2025cites this paper
• Bispecific BAFF-R/BCMA CAR T cells control growth of heterogeneous plasma cells in multiple myeloma.

  2025cites this paper
• ROR2-specific CAR T cells are effective against hematologic and solid tumors and well tolerated in mice.

  2025cites this paper
• Bispecific CAR-T vs. BCMA-Specific CAR-T: Advancing Treatment for Relapsed/Refractory Multiple Myeloma

  2025cites this paper
• T Cells Dysfunction in Multiple Myeloma

  2025cites this paper
• Timing genomic antigen loss in multiple myeloma treated with T-cell redirecting immunotherapies.

  2025cites this paper
• Acquired and Selected: Tracking Antigen Escape during T Cell-Redirecting Therapies in Multiple Myeloma.

  2025cites this paper
• Bispecific antibodies in multiple myeloma: maximizing potential through rational combination therapies.

  2025cites this paper
• Immunotherapy in multiple myeloma: advances from immune microenvironment insights to clinical application

  2025cites this paper
• Plasma cell identity escape drives resistance to anti-BCMA T-cell–redirecting therapy in multiple myeloma

  2025cites this paper
• Activin A receptor type 1C single nucleotide polymorphisms associated with esophageal squamous cell carcinoma risk in Chinese population

  2025cites this paper
• The endogenous T cell landscape is reshaped by CAR-T cell therapy and predicts treatment response in multiple myeloma

  2025cites this paper
• Mechanisms for resistance to BCMA-targeted immunotherapies in multiple myeloma.

  2025cites this paper
• Nivolumab to restore T-cell fitness in CAR-T refractory multiple myeloma

  2025cites this paper
• Combining SKY92 gene expression profiling and FISH (according to R2‐ISS) defines ultra‐high‐risk Multiple Myeloma

  2025cites this paper
• Diagnostic sequencing identifies high-risk markers and mechanisms of resistance to guide immunotherapy selection

  2025cites this paper
• Advances in RNA therapeutics and its delivery strategies against Multiple Myeloma.

  2025cites this paper
• Genetic and epigenetic mechanisms of GPRC5D loss after anti-GPRC5D CAR T-cell therapy in multiple myeloma.

  2025cites this paper
• Multi-Targeting CAR-T Cell Strategies to Overcome Immune Evasion in Lymphoid and Myeloid Malignancies

  2025cites this paper
• Sequential BCMA CAR T-cell therapy in refractory multiple myeloma

  2025cites this paper
• Perspectives on Talquetamab and its Utility in the Treatment of Multiple Myeloma: Safety, Efficacy and Place in Therapy

  2025cites this paper
• Successful sequential application of CAR T-cell-therapies in relapsed refractory multiple myeloma

  2025cites this paper
• From gene modules to gene markers: an integrated AI-human approach selects CD38 to represent plasma cell-associated transcriptional signatures

  2025cites this paper
• Atypical lymphoid proliferations associated with therapeutic intervention: a report of the 2024 EA4HP/SH lymphoma workshop

  2025cites this paper
• Multi-Omic Profiling Reveals Epigenetic Drivers of Immunotherapy Resistance in Multiple Myeloma

  2025cites this paper
• Revolutions at the frontline of multiple myeloma treatment: lessons and challenges to finding a cure

  2025cites this paper
• GSI: myeloma-cold case closed?

  2025cites this paper
• Strategies to overcome tumour relapse caused by antigen escape after CAR T therapy

  2025cites this paper
• BCMA-CAR Therapy for Multiple Myeloma in NOG Mice Prevents the Progression of Anemia and Bone Lesions

  2025cites this paper
• Deciphering response dynamics and treatment resistance from circulating tumor DNA after CAR T-cells in multiple myeloma

  2025cites this paper
• SLAMF receptors: key regulators of tumor progression and emerging targets for cancer immunotherapy

  2025cites this paper
• Bicistronic CAR-T Cell against BCMA and CD229 effectively controls myeloma even when BCMA expression is limited.

  2025cites this paper
• Targeting the CD47-SIRPalpha checkpoint in multiple myeloma

  2025cites this paper
• Insights into next-generation immunotherapy designs and tools: molecular mechanisms and therapeutic prospects

  2025cites this paper
• Challenges facing CAR T-cell immunotherapy in multiple myeloma.

  2025cites this paper
• Single cell analysis of pan-cancer tumor microenvironment in immunotherapy.

  2025cites this paper
• Boosting CAR T-cell efficacy by blocking proteasomal degradation of membrane antigens

  2025cites this paper
• Chimeric antigen receptor T-cell therapy for multiple myeloma.

  2025cites this paper
• Distinct patient, tumour and chimeric antigen receptor T‐cell characteristics are associated with initiating versus sustaining responses to idecabtagene vicleucel in relapsed and refractory multiple myeloma

  2025cites this paper
• Belantamab mafodotin does not induce B-cell maturation antigen loss or systemic immune dysfunction in multiple myeloma

  2025cites this paper
• Antigen escape in CAR‐T therapy: A tumor microenvironment perspective from hematological to solid tumors

  2025cites this paper
• Tandem CAR-T cells targeting mesothelin and MUC16 overcome tumor heterogeneity by targeting one antigen at a time

  2025cites this paper
• Plasmapheresis facilitates soluble BCMA clearance and contributes to reversing primary resistance to anti-BCMA immunotherapy in multiple myeloma

  2025cites this paper
• Boosting immune cells to combat cancer using CRISPR engineering and large-scale in vivo testing

  2025cites this paper
• In vivo chimeric antigen receptor (CAR)-T cell therapy

  2025cites this paper
• Developing SEMA4A-directed CAR T cells to overcome low BCMA antigen density in multiple myeloma.

  2025cites this paper
• Fine tuning towards the next generation of engineered T cells

  2025cites this paper
• Co-expression of an adapter CAR retains efficacy of CAR T cells after single and dual antigen loss in lymphoma.

  2025cites this paper
• Preclinical activity of allogeneic SLAMF7-specific CAR T-cells (UCARTCS1) in multiple myeloma

  2024cites this paper
• Anti-BCMA/GPRC5D bispecific CAR T cells for relapsed or refractory multiple myeloma: is 1 + 1 greater than 2?

  2024cites this paper
• T cell-redirecting therapies in hematological malignancies: Current developments and novel strategies for improved targeting

  2024cites this paper
• Fast and furious: Changing gears on the road to cure with chimeric antigen receptor T cells in multiple myeloma.

  2024cites this paper
• Clonal competition assays identify fitness signatures in cancer progression and resistance in multiple myeloma

  2024cites this paper
• Antigen escape in CAR-T cell therapy: Mechanisms and overcoming strategies.

  2024cites this paper
• Unraveling the complexity of drug resistance mechanisms to SINE, T cell-engaging therapies and CELMoDs in multiple myeloma: a comprehensive review

  2024cites this paper
• Bispecific Antibodies for Multiple Myeloma: Recent Advancements and Strategies for Increasing Their Efficacy.

  2024cites this paper
• The proteogenomic landscape of multiple myeloma reveals insights into disease biology and therapeutic opportunities

  2024cites this paper
• Chimeric antigen receptor T-cells: a review on current status and future directions for relapsed/refractory multiple myeloma

  2024cites this paper
• Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins

  2024cites this paper
• Timing antigenic escape in multiple myeloma treated with T-cell redirecting immunotherapies

  2024cites this paper
• Novel treatment strategies for hematological malignancies in the immunotherapy era

  2024cites this paper
• Charting the Course: Sequencing Immunotherapy for Multiple Myeloma.

  2024cites this paper
• BCMA/CD47-directed universal CAR-T cells exhibit excellent antitumor activity in multiple myeloma

  2024cites this paper
• Overcoming the challenges of primary resistance and relapse after CAR-T cell therapy

  2024cites this paper
• Current progress of CAR-T-cell therapy for patients with multiple myeloma

  2024cites this paper
• Single-cell genomics-based immune and disease monitoring in blood malignancies

  2024cites this paper
• Anti-Idiotypic VHHs and VHH-CAR-T Cells to Tackle Multiple Myeloma: Different Applications Call for Different Antigen-Binding Moieties

  2024cites this paper
• Complete loss of lineage defining antigens in two cases of B-cell malignancies following CAR-T therapy

  2024cites this paper
• T cell characteristics impact response and resistance to T cell-redirecting bispecific antibodies in multiple myeloma.

  2024cites this paper